NHS set to benefit from £23 million following CMA pharma probe

Contributed by: UK Government and Public Sector

Tags

Government

ViforPharma

More Like This

CMA wins drug market sharing appeal

CMA sets out provisional view on Vodafone / Three merger

PR Newswire associated0

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

PR Newswire associated0

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex

Vertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®